fda compounding glp-1 enforcement news New project announcement: HHS‑OIG is taking a closer look at FDA's oversight of compounded GLP‑1 drugs. Although shortages ended in 2025, some facilities may still be producing these drugs at scale. Our US FDA clarifies policies on

When Insurance Denies Coverage: Appeal Options and Alternatives If United Healthcare denies your GLP-1 authorization, you have appeal rights

Can be included in routines focused on maintaining overall skin care habits

Prices are subject to change without notice

This condition fundamentally arises from an imbalance in mineral metabolism parameters, including calcium, phosphorus, parathyroid hormone (PTH), vitamin D, and fibroblast growth factor-23 (FGF-23)

Swollen legs and/or ankles, generally mild and temporary in nature but reported more frequently than in other SGLT2 inhibitors like Jardiance or Farxiga ("Farxiga")